Trial Profile
Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 24 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 04 Feb 2009 New trial record.